-
Mashup Score: 1
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma - 1 month(s) ago
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma - 1 month(s) ago
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5SCIB1 Vaccine May Synergize With Nivo-Ipi Against Melanoma - 1 month(s) ago
An investigational vaccine, SCIB1, has demonstrated activity when used in combination with nivolumab and ipilimumab in patients with advanced melanoma.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma @ClevelandClinic @AACR #AACR24 #melsm https://t.co/kiJHfrBAvZ